ATE263574T1 - Verwendung von canp-inhibitoren in pharmazeutischen zubereitungen - Google Patents

Verwendung von canp-inhibitoren in pharmazeutischen zubereitungen

Info

Publication number
ATE263574T1
ATE263574T1 AT92911432T AT92911432T ATE263574T1 AT E263574 T1 ATE263574 T1 AT E263574T1 AT 92911432 T AT92911432 T AT 92911432T AT 92911432 T AT92911432 T AT 92911432T AT E263574 T1 ATE263574 T1 AT E263574T1
Authority
AT
Austria
Prior art keywords
inhibitors
therapy
contraception
neutral
viral diseases
Prior art date
Application number
AT92911432T
Other languages
English (en)
Inventor
Helen Logothetou-Rella
Original Assignee
Helen Logothetou-Rella
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helen Logothetou-Rella filed Critical Helen Logothetou-Rella
Application granted granted Critical
Publication of ATE263574T1 publication Critical patent/ATE263574T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/8107Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8139Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT92911432T 1991-06-03 1992-06-02 Verwendung von canp-inhibitoren in pharmazeutischen zubereitungen ATE263574T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GR91100238 1991-06-03
PCT/EP1992/001223 WO1992021373A1 (en) 1991-06-03 1992-06-02 USE OF CANPs-INHIBITORS IN PHARMACEUTICAL PREPARATIONS

Publications (1)

Publication Number Publication Date
ATE263574T1 true ATE263574T1 (de) 2004-04-15

Family

ID=10940713

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92911432T ATE263574T1 (de) 1991-06-03 1992-06-02 Verwendung von canp-inhibitoren in pharmazeutischen zubereitungen

Country Status (14)

Country Link
EP (1) EP0549742B1 (de)
JP (1) JP3703828B2 (de)
AT (1) ATE263574T1 (de)
AU (1) AU646961B2 (de)
CA (1) CA2088671C (de)
DE (1) DE69233337T2 (de)
DK (1) DK0549742T3 (de)
ES (1) ES2215162T3 (de)
GR (1) GR1001044B (de)
IL (1) IL102079A (de)
NO (1) NO930305L (de)
NZ (1) NZ243003A (de)
PT (1) PT100560A (de)
WO (1) WO1992021373A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT666755E (pt) * 1992-09-09 2003-09-30 Us Gov Health & Human Serv Inibicao da infeccao pelo vih
US5607831A (en) * 1993-03-25 1997-03-04 The United States Of America As Represented By The Department Of Health And Human Services In vitro methods for assessing the susceptibility of HIV-1-infected individuals to cysteine protease-mediated activation-induced programmed cell death
EP0626178A1 (de) * 1993-05-17 1994-11-30 Ciba-Geigy Ag Verwendung von Hemmstoffen von HIV-Aspartatproteasen zur Bekämpfung von Tumorerkrankungen
US20030060435A1 (en) 1994-05-31 2003-03-27 Serge Carillo Method of cancer treatment by p53 protein control

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8815962D0 (en) * 1988-07-05 1988-08-10 Univ London Pharmaceutical preparation & method for promoting reinnervation of muscle fibers

Also Published As

Publication number Publication date
EP0549742A1 (de) 1993-07-07
NO930305L (no) 1993-02-26
CA2088671A1 (en) 1992-12-04
DE69233337D1 (de) 2004-05-13
NO930305D0 (no) 1993-01-29
PT100560A (pt) 1993-07-30
NZ243003A (en) 1997-07-27
AU646961B2 (en) 1994-03-10
EP0549742B1 (de) 2004-04-07
DE69233337T2 (de) 2005-05-04
IL102079A (en) 1996-10-16
ES2215162T3 (es) 2004-10-01
DK0549742T3 (da) 2004-07-26
JPH06502188A (ja) 1994-03-10
CA2088671C (en) 1997-01-14
JP3703828B2 (ja) 2005-10-05
GR1001044B (el) 1993-04-28
WO1992021373A1 (en) 1992-12-10
AU1907392A (en) 1993-01-08

Similar Documents

Publication Publication Date Title
BR0316234A (pt) Hidroxiindóis, seu uso como inibidores de fosfodiesterase 4 e processos para a preparação dos mesmos
BR0009670A (pt) Métodos de induzir morte de células de câncer e regressão de tumor
ATE397621T1 (de) Hemmer der interaktion zwischen p53 und mdm2
NO971889L (no) Forbindelser og sammensetninger for levering av aktive midler
TR199903053T2 (xx) Benzimidazol t�revleri.
ATE201597T1 (de) Verabreichung von riluzol zur behandlung von neuro-aids
DK0516588T3 (da) Substituerede diaminophthalimider og analoger
FI940375A (fi) Peptidit, joilla on elimiä suojaavaa vaikutusta, menetelmä niiden valmistamiseksi ja niiden käyttö terapiassa
PT1149910E (pt) Composicao farmaceutica contra os tumores e as infeccoes por papilomavirus
BR9910032A (pt) Tienopirimidinas
DE58909850D1 (de) Arzneimittel zur behandlung von krebs, aids und viruserkrankungen
ATE259654T1 (de) Pharmazeutische präparate zur bekämpfung oder prophylaxe von mikroorganismen infizierten oberflächen
ATE263574T1 (de) Verwendung von canp-inhibitoren in pharmazeutischen zubereitungen
TR200103457T2 (tr) 4-Fenil-Pirimidin Türevleri.
CA2384929A1 (en) A novel angiogenesis inhibitor
EA199800526A1 (ru) Производные бензимидазола и их применение для лечения вирусных инфекций
ATE374246T1 (de) Polypeptidfragmente mit einem c-terminalen teil von katalase aus helicobacter
BR0110396A (pt) Métodos para prevenir e tratar alopecia induzida por quimioterapia ou radioterapia
ATE3416T1 (de) Pharmakologisch aktive peptide und diese enthaltende arzneimittel.
DE50113974D1 (de) Kombinationspräparate von 3-n-formylhydroxylaminopropylphosphonsäurederivaten oder 3-n-acetylhydroxylaminopropylphosphonsäurederivaten mit speziellen pharmazeutischen wirkstoffen
Sakamoto et al. Maintenance of mouse bone collagenase activity in the presence of serum protein by addition of trypsin
DE3786456T2 (de) Kombinationen von nekrose-tumor-faktoren und entzündungshemmenden mitteln für die behandlung von bösartigen und nicht bösartigen erkrankungen.
ES2013342A6 (es) Procedimiento para preparar composiciones farmaceuticas a base de ingredientes seleccionados principalmente entre alcohol, fenol, polvo de cantarida, yodo y fosforo.
NO20050067L (no) Pegylert T1249 polypeptid
SE8402199L (sv) Farmaceutiskt preparat innehallande co-dergocrin och en kalciumantagonist

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0549742

Country of ref document: EP

REN Ceased due to non-payment of the annual fee